Articles On Immutep (ASX:IMM)

Estia Health (ASX:EHE), an aged care operator with two homes in Melbourne’s 10 clusters in the sector, fell to a loss for the 2020 financial year. The company fell to a full-year loss of $116.9m after writing off goodwill, a shorthand term...

ShareCafeInvestors Are Listening As Immutep Eyes Revolutionary Cancer Treatments Immutep CEO Marc Voigt contemplates the frenetic trading in the company’s Nasdaq-listed American Depository Receipts (ADRs) after the patent approval news: the...

A quick wrap of the ASX’s key winners and losers on Wednesday, July 15. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potentially market-moving announcements during the day. Today 987 stocks rose, 400 d...

Biotech company Immutep (ASX: IMM) has been granted a US patent directed to embodiments of LAG525, a humanised form of its IMP701 antibody. The patent is directed to nucleic acid molecules which code for the LAG525 antibody in immunotherapy...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Bell Financial Group (ASX:BFG) is expecting to book a higher $23.5m first-half profit, but investors didn’t seem overly happy about it with shares dipping 5.2 per cent on Friday morning. The figure is 5 per cent up on the same period last y...

Australian immunotherapy company Immutep (ASX:IMM) has announced it has enrolled and safely dosed the last patient for stage two of Part A of its TACTI-002 Phase 2 trial.

Cancer therapeutics biotech Immutep (ASX:IMM) has enrolled and dosed the last patient for a segment of its phase 2 study into cancer treatments. The recruitment and dosing milestone was for stage 2 of Part A of its TACTI-002 phase II study....

Investors have welcomed new data from Australian biopharmaceutical company Immutep from a trial involving its eftilagimod alpha in combination with MSD's PBS-listed immunotherapy KEYTRUDA (pembrolizumab).

Biotechnology company Immutep (ASX: IMM) has published results from two ongoing clinical studies, just days after revealing it received €2.1 million (A$3.6 million) in research and development tax incentive payments from the French Governme...

ShareCafeAustralian Ethical On Emerging Biotech Company Immutep (ASX:IMM)   Immutep Ltd (ASX:IMM) is a biotechnology company that engages in the research, development, and commercialization of biological products. The company develops immu...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve been keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Pre-revenue biotech and medtech companies are still not eligible for the Jobkeeper wage subsidy according to the ATO, a double whammy for a swathe of research-driven ASX businesses with large staff costs. The Jobkeeper program allows busine...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   This week’s big themes The ca...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks, 61 were in positive territory over the last fortnight, 10 were flat and 66 saw their share prices fall. Code Name...

29 Apr 2020 - Biotech company Immutep (ASX:IMM) has today successfully completed a $12 million placement to professional, institutional and sophisticated investors.

Cancer hopeful Pharmaxis (ASX: PXS) is moving ahead with a treatment for a rare bone cancer called myelofibrosis, after a phase 1b study showed it didn’t have any negative effects on the 16 healthy volunteers who took it. The company is set...

Immunotherapy drug company Immutep is seeking a new injection of funds to finance its clinical development program. 

Immutep (ASX:IMM), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, has announced that the last patient has been enrolled and safely dosed for the second cohort of the INSIGHT-004...

Clinical trials are being shuttered in increasing numbers in Australia because of the risks posed by COVID-19, but two companies this morning say theirs are moving ahead at speed. Prescient Therapeutics (ASX:PTX) says its phase 1b study of...

Australian company Immutep (ASX:IMM) has announced it has worked with its partner EOC Pharma to review study results and they have confirmed plans to continue advancing Efti in metastatic breast cancer.

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Marc Voigt, executive director and CEO...

The ASX is cracking down on biotech and health companies disclosures around possible coronavirus-linked products. Yesterday TBG Diagnostics (ASX:TDL) was suspended as the ASX looks into why it waited until Wednesday to reveal that a COVID19...

Immutep (ASX:IMM) has announced the US FDA has approved a new Investigational New Drug application for the company's eftilagimod alpha.

Biotechnology company Immutep (ASX: IMM) has received approval from the US Food and Drug Administration for an investigational new drug (IND) application relating to its lead product candidate eftilagimod alpha for the treatment of metastat...

The cat’s not out of the bag yet, but investors are betting that when the feline does escape it will be purring with some very good news indeed. The metaphorical moggy in this case is shares in the immuno-oncological play Immutep (ASX:IMM),...

The Sydney-based biotechnology Immutep (ASX:IMM) company has released new positive data from a trial involving its immunotherapy in combination with MSD's KEYTRUDA (pembrolizumab).

Immutep (ASX:IMM) has announced it will present more mature interim TACTI-002 clinical data at the 34th German Cancer Congress in Berlin later this month.

A rebound in our big banks saw the Aussie stock market recoup half of yesterday’s heavy losses today.  It was a happier day of trading around the globe as Wall Street saw a gradual incline. The Dow Jones gained just over half a per cent...

Shares in cancer treatment specialist Immutep (IMM) are trading strong today on the back of a healthy quarterly report The report focussed largely on the company’s AIPAC clinical trial for treating breast cancer Important data from the tri...

The health sector was the most successful sector on the ASX in 2019. Various small caps made several breakthroughs including with nerve damage and macular degeneration. While cancer remains one fish that has yet to be fried there are small...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 136-odd small cap health stocks, 47 saw their share prices fall, 67 improved and 22 were flat. >> Scroll down for a table showing the performance of s...

Biotech company Immutep (IMM) has expanded part C of its TACTI-002 and AIPAC studies due to positive data Part C has been expanded to include an extra 19 patients with non-small cell lung cancer The company also remains on track to repor...

Biotech company Immutep (ASX: IMM) intends to expand ongoing development of its lead drug candidate eftilagimod alpha, otherwise known as “efti”, after welcoming positive clinical data from its TACTI-002 and AIPAC studies. The company said...

The new-look ServTech is pushing its virtual reality technology into dentistry training, being paid $500,000 by a new client for VR dental software. The company changed its name to Vection (ASX:VR1) after buying a European software developm...

Whether a day trader or a long-term investor, we often examine research released by industry experts, brokers and analysts with a view to uncovering the next big thing. The more complex the sector, the more we are likely to rely on informat...

Shares in cancer-fighting biotech Immutep (ASX:IMM) have risen to eight-month highs today, on the back of positive interim data from its phase II clinical trial in patients with non-small cell lung cancer (NSCLC). Immutep is testing whether...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

Dual Listing: When a stock gets listed on two or more stock exchanges, we say that the stock has a dual listing. Why companies go for dual listing? The biggest advantage of dual listing is that the companies get to address a large group of...

Small cap stocks are the stocks of those enterprises that have a low market capitalisation. Estimated market capitalisation of small cap companies is between $300 million and $2 billion. Small cap stocks have several advantages such as the...

Immutep (ASX:IMM) has announced "mature positive efficacy" data from its TACTI-mel Phase 1 clinical study combining its lead product candidate, eftilagimod alpha, with MSD's KEYTRUDA (pembrolizumab) in metastatic melanoma.

Biotech company Immutep (ASX:IMM) just got some positive results in a Phase I clinical trial for its cancer-fighting treatment. Phase I trials are used to test safety of a given drug, before Phase II trials which measure effectiveness. Immu...

Biotechnology company Immutep (ASX: IMM) has reported “mature positive efficacy data” from a Phase I clinical study combining lead drug candidate eftilagimod alpha with Keytruda in the treatment of metastatic melanoma. The TACTI-mel (Two AC...

Sydney-based biotechnology company Immutep (ASX: IMM) has reported a successful rollout to Part A of its TACTI-002 Phase II clinical trial for patients with previously-untreated, inoperable or metastatic non-small cell lung cancer. The comp...

Shares in Bionomics (ASX:BNO) have flown to their highest point since May as it looks redo the failed post traumatic stress disorder trial that wiped out 66 per cent of the company’s value last October. Bionomics conducted a pharmacokinetic...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Immutep (ASX:IMM) has announced that the requisite number of predefined patient responses has been exceeded in cohort 1 of Part A of the TACTI-002 Phase 2 clinical trial based on an interim analysis.

GSK has paid Australian immunotherapy company Immutep (ASX:IMM) a $7.4 million milestone payment after the first patient was dosed in the phase 2 study of GSK2831781 in ulcerative colitis.

Sydney biotech company Immutep is receiving a $7.4 million milestone payment from GSK as it begins a new trial of its drug to treat ulcerative colitis.